These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24505199)

  • 1. Serum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumab.
    Wang D; Choi KS; Lee SJ
    Korean J Ophthalmol; 2014 Feb; 28(1):32-8. PubMed ID: 24505199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal macular electroretinograms after intravitreal injections of bevacizumab for age-related macular degeneration.
    Iwata E; Ueno S; Ishikawa K; Ito Y; Uetani R; Piao CH; Kondo M; Terasaki H
    Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):4185-90. PubMed ID: 22618591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
    Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
    Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
    Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
    Kim M; Jeong S; Sagong M
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum ischemia modified albumin and vascular endothelial growth factor levels following intravitreal bevacizumab injections.
    Soiberman U; Levy R; Schwartz S; Goldstein M; Loewenstein A; Barak A
    Eur J Ophthalmol; 2014; 24(4):570-5. PubMed ID: 24338577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab versus bevacizumab and macular grid photocoagulation for macular edema in eyes with non-ischemic branch retinal vein occlusion: results from a prospective randomized study.
    Callizo J; Atili A; Striebe NA; Bemme S; Feltgen N; Hoerauf H; Bertelmann T
    Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):913-920. PubMed ID: 30610424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of choroidal neovascularization using intravitreal bevacizumab.
    Pedersen R; Soliman W; Lund-Andersen H; Larsen M
    Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab for exudative age-related macular degeneration in clinical practice.
    Jonas JB; Tao Y; Schlichtenbrede FC
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):467-70. PubMed ID: 21682590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
    Ahmadieh H; Nourinia R; Hafezi-Moghadam A; Sabbaghi H; Nakao S; Zandi S; Yaseri M; Tofighi Z; Akbarian S
    Br J Ophthalmol; 2019 Jul; 103(7):922-927. PubMed ID: 30150280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of intravitreal administration of bevacizumab on macular edema and visual acuity in age-related macular degeneration with subfoveolar choroidal neovascularisation.
    Ristić D; Vukosavljević M; Draganić B; Cerović V; Petrović N; Janićijević-Petrović M
    Vojnosanit Pregl; 2013 Jul; 70(7):660-3. PubMed ID: 23984614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration.
    Tao Y; Jonas JB
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):207-12. PubMed ID: 20415625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microperimetric changes after intravitreal bevacizumab injection for exudative age-related macular degeneration.
    Ozdemir H; Karacorlu M; Senturk F; Karacorlu SA; Uysal O
    Acta Ophthalmol; 2012 Feb; 90(1):71-5. PubMed ID: 20163371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.